Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
New York Valves 2024: Late-breaking data included a SMART Trial secondary analysis showing significantly less bioprosthetic valve dysfunction with Evolut TAV across the entire range of small annulus areas when compared with the Edwards Sapien 3™ TAV platform, and CoreValve-Evolut pooled analysis demonstrating valve performance and durability benefits versus surgery.
Medtronic, the global leader in healthcare technology, today announced the release of important clinical outcomes in two leading transcatheter valve therapies. The results for these studies were...
CRT 2024: Evolut TAVR is a safe, effective, and economically cost-effective treatment option for low-risk severe aortic stenosis patients compared to surgery up to four years
Next-Gen Evolut FX TAVI system enhances procedure ease-of-use, visualization, and predictability
40-site pilot program across US, UK, and Europe aims to introduce cutting edge AI solutions into the clinical environment to improve patient care and efficiency